Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.92 USD | +2.46% | -11.78% | +194.21% |
04-18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
03-06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
Chart: Technical Analysis
- Stock Market
- Equities
- RZLT Stock
- Charts Rezolute, Inc.